Wolfe Research initiated coverage of Verona Pharma (VRNA) with an Outperform rating and $170 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $160 from $76 at Piper Sandler
- Verona Pharma price target raised to $138 from $107 at Wells Fargo
- Strong Buy Rating for Verona Pharma’s Ohtuvayre Amidst Undervalued Peak Sales Potential and Growing Market Demand
- Verona Pharma price target raised to $116 from $92 at Roth Capital
- Verona Pharma price target raised to $100 from $90 at Cantor Fitzgerald